HIV transmission and the cost-effectiveness of methadone maintenance

American journal of public health - Tập 90 Số 7 - Trang 1100-1111 - 2000
Gregory S. Zaric1, Paul G. Barnett, Margaret L. Brandeau
1Cooperative Studies Program, Palo Alto Veterans Affairs Health Care System, Menlo Park, Calif. 94025, USA.

Tóm tắt

OBJECTIVES: This study determined the cost-effectiveness of expanding methadone maintenance treatment for heroin addiction, particularly its effect on the HIV epidemic. METHODS: We developed a dynamic epidemic model to study the effects of increased methadone maintenance capacity on health care costs and survival, measured as quality-adjusted life-years (QALYs). We considered communities with HIV prevalence among injection drug users of 5% and 40%. RESULTS: Additional methadone maintenance capacity costs $8200 per QALY gained in the high-prevalence community and $10,900 per QALY gained in the low-prevalence community. More than half of the benefits are gained by individuals who do not inject drugs. Even if the benefits realized by treated and untreated injection drug users are ignored, methadone maintenance expansion costs between $14,100 and $15,200 per QALY gained. Additional capacity remains cost-effective even if it is twice as expensive and half as effective as current methadone maintenance slots. CONCLUSIONS: Expansion of methadone maintenance is cost-effective on the basis of commonly accepted criteria for medical interventions. Barriers to methadone maintenance deny injection drug users access to a cost-effective intervention that generates significant health benefits for the general population.

Từ khóa


Tài liệu tham khảo

10.2105/AJPH.86.5.642

Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1998.

Latkin CA, 1998, Public Health Rep., 113, 151

10.1097/00042560-199802001-00022

10.1080/09540129008257740

10.1097/00002030-199603000-00008

Vlahov D, 1998, Public Health Rep., 113, 75

10.1176/ajp.156.1.27

10.1001/jama.1989.03430120118033

Metzger DS, 1993, J Acquir Immune Defic Syndr., 6, 1049

Metzger DS, 1998, Public Health Rep., 113, 97

10.3109/10826089309062178

10.1300/J069v12n01_02

10.1080/09540129408258632

10.3109/10826088509047754

10.3109/00952999209051037

10.1080/09540129208251618

Hartel DM, 1998, Public Health Rep., 113, 107

The mayor's crusade against methadone [editorial]. New York Times. August 18, 1998:A1.

10.1056/NEJM197403282901329

Gerstein DR, Johnson RA, Harwood H, Fountain D, Suter N, Malloy K. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento: California Department of Alcohol and Drug Programs; 1994.

Harwood HJ, 1988, NIDA Res Monogr., 86, 209

Harwood JJ, 1995, Res Law Policy Stud., 3, 191

10.2105/AJPH.62.10.1397

10.3109/00952997609023966

10.1001/archpsyc.1981.01780330033003

10.1046/j.1360-0443.1999.9444793.x

10.1097/00002030-199510000-00001

10.1097/00002030-199405000-00001

10.1001/archinte.152.11.2229

10.1287/mnsc.39.1.72

Hethcote H. Modeling AIDS prevention programs in a population of homosexual men. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York, NY: Raven Press; 1994:91-108.

10.1287/inte.28.3.144

10.1177/003754979807100406

Paltiel AD, 1991, J Acquir Immune Defic Syndr., 4, 795

Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K, Watson S. Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users. Report prepared for Centers for Disease Control and Prevention. San Francisco: Institute for Health Policy Studies, University of California; 1992.

10.2105/AJPH.83.8.1144

10.1016/0376-8716(96)01257-4

10.1001/jama.271.2.121

Kaplan EH, 1992, J Acquir Immune Defic Syndr., 5, 1116

10.1093/oxfordjournals.aje.a115726

10.1016/1047-2797(94)90007-8

10.1016/0376-8716(94)90092-2

10.3109/10826089509048753

10.3109/00952999108992808

10.1097/00042560-199805010-00010

The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection. Washington, DC: US General Accounting Office; 1990.

Methadone Maintenance: Some Treatment Programs Are Not Effective; Greater Federal Oversight Needed. Washington, DC: US General Accounting Office; 1990.

10.2307/2137033

10.1001/jama.235.19.2117

10.1016/0376-8716(89)90005-7

10.1016/0002-9343(78)90691-5

10.1016/0376-8716(80)90197-0

10.1001/archpsyc.1981.01780340107013

Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.

Barnett PG, Rodgers JH. The Cost of Substance Abuse Treatment: A Multivariate Cost Function Using the NDATUS. Palo Alto, Calif: VA Health Care System; 1998.

Statistical Abstract of the United States. Washington, DC: Bureau of the Census, US Dept of Commerce; 1997.

10.1097/00042560-199608010-00013

10.1097/00042560-199709010-00009

McNaghten AD. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS. Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, Ill.

Bayoumi AM, Redelmeier DA. Economic Methods for Measuring the Quality of Life Associated With HIV Infection. Toronto, Ontario: University of Toronto; 1999.

10.1023/A:1026473613487

10.1001/jama.1989.03420180101039

10.1093/clinids/10.2.377

Turner B, 1995, J Acquir Immune Defic Syndr., 9, 371

10.1097/00126334-199412000-00009

10.1016/S0740-5472(97)00132-3

10.1001/jama.1997.03550010077044

Pedersen D, 1997, Newsweek., 60

10.1001/jama.281.24.2305

Richardson L. Addicts avoid AIDS drugs, fearing they affect methadone. New York Times. July 19, 1998:A1.

10.1037/0278-6133.1.1.61

10.1046/j.1525-1497.1998.00211.x

Owens D. Economic evaluations of HIV screening. In: Holtgrave DR, ed. Handbook of HIV Prevention Policy Analysis. New York, NY: Plenum Press; 1998:81-101.

10.1136/bmj.306.6877.570

10.1016/0277-9536(93)90315-U

10.1001/jama.279.2.130

10.1287/inte.28.3.34

10.1177/0272989X9801800211

10.1001/archinte.157.17.1972

10.1097/00002030-199809000-00015

10.2105/AJPH.86.10.1442

10.1097/00002030-199703110-00013

10.1177/0193841X8901300201

Zweben JE, 1990, West J Med., 152, 588

10.2105/AJPH.85.11.1577

10.1215/03616878-15-2-357

10.1097/00002030-199201000-00016

10.1016/0740-5472(94)00084-0

10.1136/bmj.313.7052.270

10.1046/j.1360-0443.1998.9345338.x

10.1037/1064-1297.3.4.477

10.1097/00002030-199402000-00010

10.1056/NEJM198909283211306

10.1001/jama.1989.03420040099027

10.1016/0376-8716(94)01060-X

10.1016/0376-8716(94)01058-S

10.1016/0376-8716(94)01030-O

10.1098/rstb.1991.0006

10.1016/0025-5564(76)90132-2

10.1007/978-3-662-07544-9_1

10.1097/00007435-199307000-00001

10.1098/rspb.1991.0108

10.1287/inte.23.1.7

Richter AR, Brandeau ML, Owens DK. Policy analysis of preventive HIV interventions targeted to adolescents: an application of STELLA. Paper presented at: Simulation in the Medical Sciences Conference: Proceedings of the 1996 Western Multiconference; January 1996; San Diego, Calif.

10.1097/00002030-199807000-00017

10.1016/0378-8733(95)00268-S

10.1016/S0376-8716(97)00082-3

10.1016/S0376-8716(96)01279-3

10.1016/0376-8716(94)01082-V

10.1016/S0376-8716(97)00038-0

10.2105/AJPH.87.8.1289

10.1097/00042560-199604150-00011

10.1016/0277-9536(94)90301-8

10.1080/00380237.1999.10571131

10.1080/00380237.1999.10571132

10.1016/0277-9536(94)90302-6

10.1111/j.1360-0443.1992.tb02723.x

10.1111/j.1360-0443.1994.tb00880.x

10.1016/0740-5472(92)90009-D

10.1097/00002030-199714000-00012

10.1016/S0740-5472(97)00048-2

Kamlet MS, Wade M, Kupfer DJ, Frank E. Cost-utility analysis of maintenance treatment for recurrent depression: a theoretical framework and numerical illustration. In: Frank RG, Manning WG, eds. Economics and Mental Health. Baltimore, Md: Johns Hopkins University Press; 1992:267-291.

10.1097/00004714-199708000-00010

10.1001/jama.1996.03540020048028

10.1111/j.1600-0447.1990.tb03057.x

10.1093/ije/22.2.315

10.1093/ije/25.3.545

Substance Abuse and Mental Health Services Administration. National Drug and Alcoholism Treatment Unit Survey: 1991 Main Findings Report. Rockville, Md: US Dept of Health and Human Services; 1993. DHHS publication PHS (SMA) 93-2007.

Rettig RA, Yarmolinsky A. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press; 1995.

10.3109/00952999109027557

10.3109/00952999409106779

10.2105/AJPH.84.12.1965

10.1097/00002030-199702000-00014

10.2105/AJPH.82.4.573

10.3109/00952999509002708

Battjes RJ, 1991, J Acquir Immune Defic Syndr., 4, 1148

Battjes RJ, 1995, J Acquir Immune Defic Syndr., 10, 90

10.1097/00002030-199403000-00010

10.2307/2136206

10.2307/2136142

10.1001/archpedi.152.3.269

10.2307/2136144

Laumann EO, Gagnon JH, Michael RT, Michaels S. The Social Organization of Sexuality: Sexual Practices in the United States. Chicago, Ill: University of Chicago Press; 1994.

10.2307/2136143

10.2105/AJPH.83.10.1400

10.1001/archinte.158.3.253

10.2307/2135805

10.1001/jama.258.6.788

10.1001/jama.266.12.1664

10.1093/oxfordjournals.aje.a009276

Samuel MC, Mohr MS, Speed TP, Winkelstein W. Infectivity of HIV by anal and oral intercourse among homosexual men: estimates from a prospective study in San Francisco. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York, NY: Raven Press; 1994:423-438.

10.1056/NEJM199408113310601

10.1038/333514a0

10.1016/0277-9536(93)90352-5

10.1016/S0277-9536(96)00258-4

10.7326/0003-4819-113-10-740

10.1080/15298669091370329

Cheng FK, 1995, Clin Perform Qual Health Care., 3, 147

10.1056/NEJM198710293171806

10.1056/NEJM199604183341602

10.1056/NEJM199709113371102

10.1056/NEJM199709113371101

Hogg RS, 1999, CMAJ., 160, 659

10.1097/00002030-199902040-00013

10.7326/0003-4819-122-9-199505010-00001

10.1136/bmj.314.7078.409

10.1097/00005650-199601000-00004

Bureau of Labor Statistics. Consumer Price Index. Washington, DC: US Dept of Labor; 1998.

Thông tin
Thông tin xuất bản

American journal of public health

Tập 90 Số 7

1100-1111

Thông tin tác giả